Christophe Louvet

29.2k total citations · 9 hit papers
278 papers, 17.8k citations indexed

About

Christophe Louvet is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Christophe Louvet has authored 278 papers receiving a total of 17.8k indexed citations (citations by other indexed papers that have themselves been cited), including 229 papers in Oncology, 100 papers in Pulmonary and Respiratory Medicine and 62 papers in Surgery. Recurrent topics in Christophe Louvet's work include Colorectal Cancer Treatments and Studies (147 papers), Cancer Treatment and Pharmacology (73 papers) and Pancreatic and Hepatic Oncology Research (63 papers). Christophe Louvet is often cited by papers focused on Colorectal Cancer Treatments and Studies (147 papers), Cancer Treatment and Pharmacology (73 papers) and Pancreatic and Hepatic Oncology Research (63 papers). Christophe Louvet collaborates with scholars based in France, Belgium and Canada. Christophe Louvet's co-authors include Aimery de Gramont, Thierry André, Christophe Tournigand, Gérard Lledo, Olivier Bouché, F. Morvan, Bruno Landi, Pascal Hammel, Marc Buyse and Arié Figer and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Christophe Louvet

265 papers receiving 17.3k citations

Hit Papers

Leucovorin and Fluorouracil With or Without Oxaliplatin a... 1997 2026 2006 2016 2000 2003 2008 2005 1997 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
    2000 3.0k citations Aimery de Gramont, Arié Figer et al. Journal of Clinical Oncology profile →
  2. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
    2003 2.3k citations Christophe Tournigand, Thierry André et al. Journal of Clinical Oncology profile →
  3. KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
    2008 1.1k citations Astrid Lièvre, Jean‐Baptiste Bachet et al. Journal of Clinical Oncology profile →
  4. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
    2005 760 citations Christophe Louvet, Pascal Hammel et al. Journal of Clinical Oncology profile →
  5. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
    1997 709 citations Aimery de Gramont, Philippe Rougier et al. Journal of Clinical Oncology profile →
  6. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
    2016 685 citations Pascal Hammel, F. Huguet et al. profile →
  7. OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study
    2006 583 citations Christophe Tournigand, Andrés Cervantes et al. Journal of Clinical Oncology profile →
  8. Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
    2022 220 citations Thierry André, David Tougeron et al. Journal of Clinical Oncology profile →
  9. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial
    2024 57 citations Olivier Bouché, Valérie Boige et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christophe Louvet France 54 14.9k 6.1k 4.2k 3.6k 2.5k 278 17.8k
Steven R. Alberts United States 60 12.4k 0.8× 5.2k 0.9× 4.6k 1.1× 3.3k 0.9× 2.3k 0.9× 311 17.1k
Werner Scheithauer Austria 57 14.5k 1.0× 5.4k 0.9× 4.1k 1.0× 4.6k 1.3× 2.3k 0.9× 350 18.2k
Aimery de Gramont France 64 20.1k 1.4× 6.8k 1.1× 5.3k 1.3× 4.7k 1.3× 2.4k 1.0× 333 25.0k
Arié Figer Israel 35 11.6k 0.8× 4.1k 0.7× 2.6k 0.6× 3.4k 0.9× 2.1k 0.9× 107 14.6k
Valérie Boige France 63 9.5k 0.6× 6.2k 1.0× 5.7k 1.4× 3.9k 1.1× 1.9k 0.8× 287 17.6k
Ian Chau United Kingdom 56 13.1k 0.9× 7.2k 1.2× 5.4k 1.3× 3.2k 0.9× 2.4k 1.0× 473 18.8k
Ho Yeong Lim South Korea 58 6.6k 0.4× 5.7k 0.9× 3.6k 0.9× 4.4k 1.2× 2.6k 1.1× 369 15.0k
Michael J. Overman United States 58 11.2k 0.8× 3.9k 0.6× 3.9k 0.9× 2.3k 0.6× 3.1k 1.2× 447 16.5k
Joon Oh Park South Korea 54 9.2k 0.6× 7.6k 1.2× 4.3k 1.0× 1.6k 0.4× 2.9k 1.2× 387 16.2k
Marc Ychou France 59 16.1k 1.1× 7.7k 1.3× 4.8k 1.1× 2.9k 0.8× 5.1k 2.1× 322 22.1k

Countries citing papers authored by Christophe Louvet

Since Specialization
Citations

This map shows the geographic impact of Christophe Louvet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Louvet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Louvet more than expected).

Fields of papers citing papers by Christophe Louvet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Louvet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Louvet. The network helps show where Christophe Louvet may publish in the future.

Co-authorship network of co-authors of Christophe Louvet

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Louvet. A scholar is included among the top collaborators of Christophe Louvet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Louvet. Christophe Louvet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vienot, Angélique, Déwi Vernerey, Adeline Bouard, et al.. (2025). Stanniocalcin 1 in Patients with Refractory Colorectal Cancer Treated with Regorafenib: A Post Hoc Biomarker Analysis of the TEXCAN and CORRECT Trials. Cancer Research Communications. 5(2). 287–294. 2 indexed citations
2.
Léary, Alexandra, Christophe Schneider, Elisa Yaniz‐Galende, et al.. (2023). CD47 expression in ovarian cancer: Dynamic correlation with lymphocyte and macrophage features as well as thrombospondin-1 (TSP-1) under neoadjuvant chemotherapy.. Journal of Clinical Oncology. 41(16_suppl). 5569–5569.
3.
Gallois, Claire, Thierry André, Sophie Mouillet‐Richard, et al.. (2023). Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials.. Journal of Clinical Oncology. 41(16_suppl). 3523–3523.
4.
François, Éric, Thomas Aparicio, Karine Le Malicot, et al.. (2022). SOCRATE-PRODIGE 55 trial: A randomized phase II study to evaluate second-line ramucirumab alone or with paclitaxel in older patients with advanced gastric cancer. Digestive and Liver Disease. 54(6). 747–754. 2 indexed citations
5.
André, Thierry, David Tougeron, Guillaume Piessen, et al.. (2022). Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. Journal of Clinical Oncology. 41(2). 255–265. 220 indexed citations breakdown →
6.
Watson, Sarah, Joanna Cyrta, Marine Lefèvre, et al.. (2021). Hyperprogressive Disease After Pembrolizumab Treatment in Advanced Epstein-Barr Virus–Associated Gastric Adenocarcinoma With ERBB2 Amplification. JCO Precision Oncology. 5(5). 370–377.
7.
Taı̈eb, Julien, Valérie Taly, Julie Henriques, et al.. (2021). Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial. Clinical Cancer Research. 27(20). 5638–5646. 71 indexed citations
8.
Schernberg, Antoine, Déwi Vernerey, David Goldstein, et al.. (2021). Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 110(4). 1022–1031. 7 indexed citations
9.
Perrier, Hervé, Marine Lefèvre, Christophe Louvet, et al.. (2020). Drastic Reduction of Turnaround Time After Implementation of a Fully Automated Assay for RAS-BRAF Mutations in Colorectal Cancer: A Pilot Prospective Study in Real-life Conditions. Pathology & Oncology Research. 26(4). 2469–2473. 2 indexed citations
10.
Phelip, Jean–Marc, David Tougeron, David Léonard, et al.. (2019). Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Digestive and Liver Disease. 51(10). 1357–1363. 70 indexed citations
11.
Touchefeu, Yann, Rosine Guimbaud, Christophe Louvet, et al.. (2018). Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial. Gastric Cancer. 22(3). 577–586. 5 indexed citations
12.
Sargent, Daniel J., Qian Shi, Sharlene Gill, et al.. (2014). Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study. Clinical Cancer Research. 20(16). 4361–4369. 8 indexed citations
13.
Zaanan, Aziz, Jean–François Fléjou, Jean‐François Emile, et al.. (2011). Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy. Clinical Cancer Research. 17(23). 7470–7478. 64 indexed citations
14.
Gramont, Aimery de, Aimery de Gramont, Armand de Gramont, et al.. (2011). From Chemotherapy to Targeted Therapy in Adjuvant Treatment for Stage III Colon Cancer. Seminars in Oncology. 38(4). 521–532. 27 indexed citations
15.
Chibaudel, Benoist, Frédérique Maindrault‐Gœbel, Gérard Lledo, et al.. (2009). Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study. Journal of Clinical Oncology. 27(34). 5727–5733. 262 indexed citations
16.
Lièvre, Astrid, Jean‐Baptiste Bachet, Valérie Boige, et al.. (2008). KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. Journal of Clinical Oncology. 26(3). 374–379. 1141 indexed citations breakdown →
17.
Lièvre, Astrid, Jean‐Baptiste Bachet, Marc Ychou, et al.. (2007). KRAS mutations in colorectal cancer is a predictive factor of response and progression free survival in patients treated with Cetuximab.. Cancer Research. 67. 5671–5671. 7 indexed citations
18.
Tournigand, Christophe, Thierry André, Emmanuel Achille, et al.. (2003). FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. Journal of Clinical Oncology. 22(2). 229–237. 2290 indexed citations breakdown →
19.
Gramont, Aimery de, Arié Figer, Michel Seymour, et al.. (2000). Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. Journal of Clinical Oncology. 18(16). 2938–2947. 3040 indexed citations breakdown →
20.
Gramont, Aimery de, M Krulik, Jean Cady, et al.. (1988). High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. European Journal of Cancer and Clinical Oncology. 24(9). 1499–1503. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steven R. Alberts Breakdown of academic impact, for papers by Werner Scheithauer Breakdown of academic impact, for papers by Aimery de Gramont Breakdown of academic impact, for papers by Arié Figer Breakdown of academic impact, for papers by Valérie Boige Breakdown of academic impact, for papers by Ian Chau Breakdown of academic impact, for papers by Ho Yeong Lim Breakdown of academic impact, for papers by Michael J. Overman Breakdown of academic impact, for papers by Joon Oh Park Breakdown of academic impact, for papers by Marc Ychou
Rankless by CCL
2026